Stockscreener 앱 받기
0.88
60.89%
-1.37
시간 외 거래:
.86
-0.02
-2.27%
전일 마감가:
$2.25
열려 있는:
$0.7648
하루 거래량:
33.32M
Relative Volume:
17.35
시가총액:
$120.05M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-0.6331
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
-53.68%
1개월 성능:
-49.43%
6개월 성능:
-42.48%
1년 성능:
-50.84%
1일 변동 폭
$0.75
$1.32
1주일 범위
$0.75
$2.36
52주 변동 폭
$0.75
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
0.88 | 120.05M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance
Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView
Sector Update: Health Care - TradingView
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - Asianet Newsable
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters.com
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks
Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus.com
Milestone flagging following CRL - The Pharma Letter
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com
Milestone Pharma says FDA declined to approve heart disorder therapy - MSN
Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com
FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus.com
Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma
Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha
FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com
Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView
FDA flags issues with Milestone’s new drug application - Investing.com India
Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks
US FDA declines to approve Milestone's heart rhythm nasal spray - TradingView
FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com
Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - Marketscreener.com
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha
HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World
Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - The Manila Times
Breakthrough PSVT Treatment Data: Etripamil Proves Effective for Multiple Episodes - StockTitan
Jones Financial Companies Lllp Raises Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
HC Wainwright Has Negative Outlook of MIST FY2028 Earnings - Defense World
Milestone Pharmaceuticals sets annual meeting date - Investing.com
Milestone Pharmaceuticals sets annual meeting date By Investing.com - Investing.com UK
PDUFA Date Nearing for New PSVT Drug - Streetwise Reports
Milestone Pharma Expands Sale Agreement, Increases Offering By Investing.com - Investing.com Canada
SEC Form 424B5 filed by Milestone Pharmaceuticals Inc. - Quantisnow
Milestone Pharmaceuticals enters open market sale agreement with Jefferies -March 18, 2025 at 05:51 pm EDT - Marketscreener.com
Milestone Pharma Expands Sale Agreement, Increases Offering - Investing.com India
Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright - Defense World
Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects - TipRanks
Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength - TipRanks
Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates - Nasdaq
Milestone Pharmaceuticals Inc. SEC 10-K Report - TradingView
Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Thursday - Defense World
3 Reasons GNK is Risky and 1 Stock to Buy Instead - The Globe and Mail
Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments - CNBCTV18
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.34%
자본화:
|
볼륨(24시간):